focus -WSS

focus

author：Wikipedia 2025-09-28 23:05:27 - browse：4692

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Adam's Biotech Scorecard: Do Sarepta's exon

WSS

St. Louis police protesters begin picking up checks in $4.9 million settlement

Sweden knocks USA out of World Cup in penalty kicks

What will save rural psychiatry services? Higher Medicaid payments

Childbirth

Childbirth

Election results set back Medicaid expansion plans

leisure time

focus

focus

How one medical school became remarkably diverse

Tuberculosis patients need more than just free medication

Trump demands the U.S. pay no more for drugs than other countries … again

Lab trade group sues FDA to halt regulation of lab

Drug repurposing or repositioning? The language matters

Insmed lung disease drug hits target in key Phase 3 trial

Duchenne breakthrough therapy leaves behind pioneering families

'Brian's Song' at 50 still offers lessons about cancer for today

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Scientists successfully use ultrasound imaging to map brain activity

explore

What will save rural psychiatry services? Higher Medicaid payments

NFL doctors' conflicts of interest could endanger players, report says

Stigma and the return of syphilis

Dark money group runs ads on China biotech bill

Prosthetic arm enables patients to feel the objects they grip

First Opinion Podcast: What happens when kids become caregivers?

entertainment

hotspot

entertainment

Wikipedia